Novavax Inc (NVAX)
8.47
+0.43
(+5.35%)
USD |
NASDAQ |
Nov 22, 16:00
8.44
-0.03
(-0.35%)
After-Hours: 20:00
Novavax Free Cash Flow: -112.35M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | -112.35M |
| June 30, 2024 | -23.57M |
| March 31, 2024 | -514.43M |
| December 31, 2023 | -772.77M |
| September 30, 2023 | -726.79M |
| June 30, 2023 | -736.98M |
| March 31, 2023 | -752.74M |
| December 31, 2022 | -508.92M |
| September 30, 2022 | -727.81M |
| June 30, 2022 | -813.92M |
| March 31, 2022 | -489.18M |
| December 31, 2021 | 265.46M |
| September 30, 2021 | 453.65M |
| June 30, 2021 | 592.76M |
| March 31, 2021 | 575.37M |
| December 31, 2020 | -97.16M |
| September 30, 2020 | 49.46M |
| June 30, 2020 | 32.06M |
| March 31, 2020 | -110.30M |
| December 31, 2019 | -138.48M |
| September 30, 2019 | -160.30M |
| June 30, 2019 | -161.59M |
| March 31, 2019 | -171.38M |
| December 31, 2018 | -186.20M |
| September 30, 2018 | -184.46M |
| Date | Value |
|---|---|
| June 30, 2018 | -195.95M |
| March 31, 2018 | -169.31M |
| December 31, 2017 | -148.66M |
| September 30, 2017 | -172.36M |
| June 30, 2017 | -193.28M |
| March 31, 2017 | -247.20M |
| December 31, 2016 | -276.97M |
| September 30, 2016 | -268.60M |
| June 30, 2016 | -235.22M |
| March 31, 2016 | -184.35M |
| December 31, 2015 | -144.36M |
| September 30, 2015 | -107.15M |
| June 30, 2015 | -93.12M |
| March 31, 2015 | -88.32M |
| December 31, 2014 | -74.28M |
| September 30, 2014 | -65.41M |
| June 30, 2014 | -62.99M |
| March 31, 2014 | -60.34M |
| December 31, 2013 | -51.14M |
| September 30, 2013 | -43.25M |
| June 30, 2013 | -32.52M |
| March 31, 2013 | -29.70M |
| December 31, 2012 | -22.57M |
| September 30, 2012 | -20.24M |
| June 30, 2012 | -18.04M |
Free Cash Flow Range, Past 5 Years
-813.92M
Minimum
Jun 2022
592.76M
Maximum
Jun 2021
-227.83M
Average
-125.41M
Median
Free Cash Flow Benchmarks
| Pfizer Inc | 8.227B |
| Moderna Inc | -3.956B |
| Inovio Pharmaceuticals Inc | -111.18M |
| Baxter International Inc | 391.00M |
| Halozyme Therapeutics Inc | 392.71M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -144.81M |
| Cash from Investing (Quarterly) | 31.91M |
| Cash from Financing (Quarterly) | -0.097M |
| Free Cash Flow Per Share (Quarterly) | -0.9174 |
| Free Cash Flow to Equity (Quarterly) | -147.24M |
| Free Cash Flow to Firm (Quarterly) | -142.63M |
| Free Cash Flow Yield | -9.00% |